AR027437A1 - Derivados de purina - Google Patents

Derivados de purina

Info

Publication number
AR027437A1
AR027437A1 ARP010100690A ARP010100690A AR027437A1 AR 027437 A1 AR027437 A1 AR 027437A1 AR P010100690 A ARP010100690 A AR P010100690A AR P010100690 A ARP010100690 A AR P010100690A AR 027437 A1 AR027437 A1 AR 027437A1
Authority
AR
Argentina
Prior art keywords
compounds
preparation
purina
derivatives
purina derivatives
Prior art date
Application number
ARP010100690A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR027437A1 publication Critical patent/AR027437A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)

Abstract

La presente invencion se refiere a compuestos de formula (1) y a sus sales y solvatos farmacéuticamente aceptables, y a procedimientos para su preparacion,intermedios usados en su preparacion, composiciones que los contengan y a los usos de tales com puestos para fabricar medicamento. (Los valores de lossustituyentes figuran en la memoria descriptiva).
ARP010100690A 2000-02-18 2001-02-15 Derivados de purina AR027437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0003960.2A GB0003960D0 (en) 2000-02-18 2000-02-18 Purine derivatives

Publications (1)

Publication Number Publication Date
AR027437A1 true AR027437A1 (es) 2003-03-26

Family

ID=9886026

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100690A AR027437A1 (es) 2000-02-18 2001-02-15 Derivados de purina

Country Status (39)

Country Link
US (1) US6525032B2 (es)
EP (1) EP1255764B8 (es)
JP (1) JP2004508284A (es)
KR (1) KR20030036138A (es)
CN (1) CN1400975A (es)
AP (1) AP2002002598A0 (es)
AR (1) AR027437A1 (es)
AT (1) ATE325807T1 (es)
AU (1) AU2001230440A1 (es)
BG (1) BG106906A (es)
BR (1) BR0108408A (es)
CA (1) CA2400619A1 (es)
CO (1) CO5271668A1 (es)
CR (1) CR6722A (es)
CZ (1) CZ20022703A3 (es)
DE (1) DE60119492T2 (es)
EA (1) EA004987B1 (es)
EE (1) EE200200452A (es)
ES (1) ES2260199T3 (es)
GB (1) GB0003960D0 (es)
GT (1) GT200100027A (es)
HN (1) HN2001000027A (es)
HR (1) HRP20020676A2 (es)
HU (1) HUP0301055A2 (es)
IL (1) IL150543A0 (es)
IS (1) IS6458A (es)
MA (1) MA26873A1 (es)
MX (1) MXPA02008068A (es)
NO (1) NO20023894L (es)
NZ (1) NZ519971A (es)
OA (1) OA12177A (es)
PA (1) PA8511801A1 (es)
PE (1) PE20011122A1 (es)
PL (1) PL357220A1 (es)
SK (1) SK11692002A3 (es)
SV (1) SV2002000317A (es)
TN (1) TNSN01028A1 (es)
WO (1) WO2001060835A1 (es)
ZA (1) ZA200206526B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7214665B2 (en) * 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
GB0129270D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
GB0129397D0 (en) * 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE602005020286D1 (de) 2004-05-26 2010-05-12 Inotek Pharmaceuticals Corp Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
NZ553288A (en) * 2004-08-02 2010-12-24 Univ Virginia 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
JP5011112B2 (ja) * 2004-09-20 2012-08-29 イノテック ファーマシューティカルズ コーポレイション プリン誘導体を含有する炎症性疾患の治療用医薬
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
AU2006320578B2 (en) * 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
JP2008285478A (ja) * 2007-04-16 2008-11-27 Santen Pharmaceut Co Ltd アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
AU2010284972A1 (en) 2009-08-20 2012-03-08 Novartis Ag Heterocyclic oxime compounds
SI2523669T1 (sl) 2010-01-11 2017-05-31 Inotek Pharmaceuticals Corporation Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka
BR112012023749A2 (pt) 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
KR20140128974A (ko) 2012-01-26 2014-11-06 이노텍 파마슈티컬스 코포레이션 ((2r,3s,4r,5r)-5-(6-(시클로펜틸아미노)-9h-퓨린-9-일)-3,4-디히드록시테트라히드로푸란-2-일) 메틸 니트레이트의 무수 다형체들 및 이들의 제조 방법들
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174541A1 (de) 2014-07-28 2017-06-07 Technische Universität Dresden Thymin- und chinazolin-dion-derivate zur hemmung von hsp27
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
TWI771266B (zh) * 2015-03-13 2022-07-11 瑞典商杜比國際公司 解碼具有增強頻譜帶複製元資料在至少一填充元素中的音訊位元流
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
IS6458A (is) 2002-07-05
SV2002000317A (es) 2002-07-16
NO20023894D0 (no) 2002-08-16
ES2260199T3 (es) 2006-11-01
GB0003960D0 (en) 2000-04-12
ATE325807T1 (de) 2006-06-15
CA2400619A1 (en) 2001-08-23
OA12177A (en) 2006-05-09
EP1255764B8 (en) 2006-06-28
HRP20020676A2 (en) 2004-12-31
ZA200206526B (en) 2003-10-16
CR6722A (es) 2003-11-25
PA8511801A1 (es) 2002-02-21
NO20023894L (no) 2002-10-01
JP2004508284A (ja) 2004-03-18
EA004987B1 (ru) 2004-10-28
WO2001060835A1 (en) 2001-08-23
EE200200452A (et) 2003-12-15
CN1400975A (zh) 2003-03-05
PE20011122A1 (es) 2001-11-06
SK11692002A3 (sk) 2003-11-04
MXPA02008068A (es) 2004-04-05
PL357220A1 (en) 2004-07-26
HUP0301055A2 (hu) 2003-08-28
EA200200770A1 (ru) 2002-12-26
NZ519971A (en) 2004-04-30
AP2002002598A0 (en) 2002-09-30
TNSN01028A1 (fr) 2005-11-10
GT200100027A (es) 2001-12-19
IL150543A0 (en) 2003-02-12
EP1255764A1 (en) 2002-11-13
DE60119492T2 (de) 2006-11-09
EP1255764B1 (en) 2006-05-10
US20010020089A1 (en) 2001-09-06
CZ20022703A3 (cs) 2003-09-17
MA26873A1 (fr) 2004-12-20
CO5271668A1 (es) 2003-04-30
US6525032B2 (en) 2003-02-25
WO2001060835A8 (en) 2001-11-29
AU2001230440A1 (en) 2001-08-27
BR0108408A (pt) 2002-11-26
BG106906A (en) 2003-04-30
KR20030036138A (ko) 2003-05-09
HN2001000027A (es) 2001-09-11
DE60119492D1 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
AR027437A1 (es) Derivados de purina
PA8528501A1 (es) Derivados de purina
AR023275A1 (es) Derivados de la purina
CU23240B7 (es) Derivados de 2-aminocarbonil-9h-purina
PA8503601A1 (es) Derivados de purina
CR8859A (es) Derivados de piridina
CR7069A (es) Derivados de pirazol para el tratamiento de vih
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
UY26797A1 (es) Derivados de purina
HN2000000097A (es) Derivados de purina
ES2196377T3 (es) Derivados de naftiridina.
PA8437301A1 (es) Derivados de indazol
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
AR015103A1 (es) Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones que los contienen e intermediarios
AR027263A1 (es) Derivados de 1,3-dihidro-2h-indol-2-ona, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen.
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
AR050260A1 (es) Derivados de diarilmetilpiperazinas, su preparacion y su utilizacion
AR008291A1 (es) Derivados de tetrahidroisoquinolina, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso para la preparacionde un medicamento.
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
PA8450901A1 (es) Derivados de eritromicina
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure